Mercury Laboratories Limited
BSE: MERCURYLAB · Pharmaceuticals · sector
₹734.10BSE close 2026-10-26
Key numbers
Market cap₹88 cr
Price₹734.10
52w high / low₹930 / ₹621
P/E21.2xSector median 27.9x
P/B1.5xSector median 2.9x
Book value₹484.0
Dividend yield0.48%Sector median 0.48%
ROE7.5%Sector median 11.7%
ROCE9.2%Sector median 12.3%
OPM10.2%Sector median 14.0%
Debt / equity0.13xSector median 0.16x
EV/EBITDA11.9xSector median 18.6x
Interest cover11.5x
Current ratio3.85x
Sales growth 3y+0.3%Sector median +9.6%
Profit growth 3y-4.7%Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹6 cr vs borrowings ₹7 cr (FY26): borrowings are higher by ₹1 cr.
- Operating profit covered interest 11.5x in the last 12 months.
- Other income was 44% of net profit in the last 12 months.
- Dividend paid in 4 of the last 5 financial years.
- Price ₹734.10 on 2026-10-26: -21.1% from the 52-week high, +18.3% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹1,117.75 · low ₹713.20
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 21 | 18 | 19 | 18 | 20 | 16 |
| EBITDA | 2 | 2 | 2 | 2 | 2 | 1 |
| OPM % | 10.3% | 13.0% | 11.2% | 11.6% | 10.0% | 7.5% |
| Other income | 0 | 0 | 1 | 0 | 1 | 0 |
| Net profit | 1 | 1 | 2 | 1 | 1 | 0 |
| EPS (₹) | 9.25 | 8.06 | 13.69 | 8.31 | 10.21 | 2.48 |
| Revenue YoY | -1.1% | -12.0% | ||||
| Profit YoY | +10.8% | -69.1% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 58 | 75 | 76 | 75 | 76 | 74 |
| EBITDA | 7 | 9 | 9 | 7 | 9 | 7 |
| Net profit | 4 | 6 | 6 | 3 | 5 | 4 |
| EPS (₹) | 30.72 | 46.49 | 47.12 | 26.21 | 40.28 | 34.69 |
| Revenue growth | +30.1% | +0.3% | -0.6% | +1.1% | – | |
| Profit growth | +51.2% | +1.3% | -44.4% | +53.8% | – | |
| Dividend / share (₹) | – | 3.50 | 3.50 | 3.50 | 3.50 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +0.3% | – | – |
| Net profit | -4.7% | – | – |
| EPS | -4.7% | – | – |
| Share price | – | -12.1% (2y) | -17.7% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 54 | 58 |
| Borrowings | 4 | 7 |
| Cash & equivalents | 2 | 6 |
| Total assets | 74 | 79 |
| Fixed assets | 25 | 24 |
| Capital work in progress | 9 | 10 |
| Investments | 0 | 0 |
| Receivables | 26 | 26 |
| Inventory | 7 | 7 |
| Payables | 10 | 6 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 4 | 4 |
| Cash from investing | -9 | -3 |
| Cash from financing | -1 | 3 |
| Capex | 9 | 3 |
| Free cash flow | -5 | 1 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 5.9% | 8.3% |
| ROCE % | 9.0% | 11.0% |
| Debtor days | 125 | 124 |
| Inventory days | 91 | 88 |
| Payable days | 124 | 77 |
| Cash conversion cycle (days) | 92 | 135 |
| Working capital days | 122 | 160 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| MERCURYLAB | ₹88 cr | 21.2x | 1.5x | 7.5% | 9.2% | 10.2% | +0.3% | 0.48% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-09-21 | Dividend | Final Dividend Rs 3.5 |
| 2025-08-06 | Dividend | Final Dividend Rs 3.5 |
| 2024-09-20 | Dividend | Final Dividend Rs 3.5 |
| 2023-09-20 | Dividend | Final Dividend Rs 3.5 |
| 2022-09-19 | Dividend | Final Dividend Rs 3.5 |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | MERCURYLAB |
| BSE code | 538964 |
| ISIN | INE947G01011 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-24 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.